Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)’s share price shot up 2.1% during mid-day trading on Thursday . The stock traded as high as $22.12 and last traded at $21.83, with a volume of 317,586 shares traded. The stock had previously closed at $21.38.

Several research firms have issued reports on SUPN. Jefferies Group reiterated a “buy” rating and set a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Piper Jaffray Cos. cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research report on Monday, July 18th. Northland Securities cut Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research report on Monday, July 18th. Finally, Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $24.50.

The firm has a 50 day moving average price of $22.07 and a 200-day moving average price of $18.24. The stock has a market cap of $1.09 billion and a price-to-earnings ratio of 44.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.05. The firm earned $50.40 million during the quarter, compared to analysts’ expectations of $49.67 million. During the same period in the previous year, the company posted $0.03 earnings per share. The company’s quarterly revenue was up 43.6% compared to the same quarter last year. On average, equities analysts expect that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current year.

In other news, CFO Gregory S. Patrick sold 3,395 shares of the stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $22.00, for a total value of $74,690.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.